Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C34.129601%2C-117.971001%7C34.110001%2C-118.290001%7C34.061401%2C-118.205002%7C39.75%2C-104.839996%7C43.59%2C-116.199997%7C33.61891%2C-117.92895%7C39.742699%2C-104.838997%7C38.99067%2C-77.02609%7C42.266079%2C-83.655507%7C42.367199%2C-83.085197%7C44.969242%2C-93.361771%7C45.783448%2C-108.596353%7C43.675999%2C-72.273102%7C40.496399%2C-74.4487%7C40.846199%2C-73.845001%7C39.137402%2C-84.5037%7C39.24043%2C-84.389269%7C45.527%2C-122.613998%7C39.950001%2C-75.300003%7C40.17844%2C-75.12851%7C35.110802%2C-89.7985%7C30.344801%2C-97.752701%7C32.73%2C-97.32%7C29.707199%2C-95.396698%7C32.344002%2C-95.290604%7C39.130001%2C-77.529999%7C47.246201%2C-122.447998%7C43.060799%2C-88.028397%7C41.258393%2C-96.042142)
Participating Centers
There are 29 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Alectinib is a tyrosine kinase inhibitor for ALK (anaplastic lymphoma kinase) gene mutations.
- Entrectinib is a first generation TRK inhibitor that is used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors.
- Idasanutlin
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.